ABT
Abbott Laboratories
Price Chart
Latest Quote
$91.07
+0.29 (+0.32%)
Current Price
| Previous Close | $90.78 |
| Open | $91.75 |
| Day High | $92.73 |
| Day Low | $90.96 |
| Volume | 11,886,184 |
Stock Information
| Quarterly Dividend / Yield | $2.52 / 2.78% |
| Shares Outstanding | 1.74B |
| Quarterly Dividend Yield | 2.78% |
| Quarterly Dividend | $2.52 |
| Total Debt | $34.14B |
| Cash Equivalents | $7.30B |
| Revenue | $45.13B |
| Net Income | $6.25B |
| Sector | Healthcare |
| Industry | Medical Devices |
| Market Cap | $158.63B |
| P/E Ratio | 25.51 |
| EPS (TTM) | $3.57 |
| Exchange | NYQ |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $185.60B |
| Sales | $45.13B |
| Income | $6.25B |
| Book/sh | $29.89 |
| Cash/sh | $4.19 |
| Employees | 122K |
Financial Ratios
| Quick Ratio | 0.84 |
| Current Ratio | 1.39 |
| Debt/Eq | 64.77 |
| EPS Growth TTM | -18.70% |
Returns & Margins
| ROA | 5.59% |
| ROE | 12.33% |
| Gross Margin | 56.50% |
| Operating Margin | 13.47% |
| Profit Margin | 13.90% |
Ownership
| Insider Ownership | 0.49% |
| Institutional Ownership | 82.66% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 15.02 |
| PEG | 1.29 |
| P/S | 3.51 |
| P/B | 3.05 |
Analyst Data
| Recommendation | buy |
| Target Price | $117.29 |
Technical Indicators
| SMA20 | $86.63 |
| SMA50 | $92.38 |
| SMA200 | $114.49 |
| RSI | 70.75 |
| ATR | 2.0743 |
| Shares Float | 1.73B |
| Short Float | 1.49% |
| Short Ratio | 1.63 |
| Volatility | 0.62 |
| Rel Volume | 0.99 |
Performance History
| Week | +6.39% |
| Month | +5.53% |
| Quarter | -16.36% |
| 6 Months | -26.49% |
| YTD | -25.83% |
| Year | -30.11% |
| 3 Years | -5.18% |
| 5 Years | -14.24% |
| 10 Years | +180.39% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-05 | $91.07 | 11,886,184 |
| 2026-06-04 | $90.78 | 14,153,200 |
| 2026-06-03 | $86.99 | 10,448,100 |
| 2026-06-02 | $86.97 | 10,283,600 |
| 2026-06-01 | $87.78 | 10,561,100 |
| 2026-05-29 | $85.60 | 21,143,600 |
| 2026-05-28 | $86.30 | 10,151,700 |
| 2026-05-27 | $85.68 | 10,813,900 |
| 2026-05-26 | $86.67 | 10,249,200 |
| 2026-05-22 | $87.41 | 9,516,400 |
| 2026-05-21 | $87.77 | 8,524,200 |
| 2026-05-20 | $88.38 | 7,834,400 |
| 2026-05-19 | $88.82 | 11,693,500 |
| 2026-05-18 | $87.91 | 12,347,000 |
| 2026-05-15 | $84.47 | 13,208,600 |
| 2026-05-14 | $84.90 | 11,018,400 |
| 2026-05-13 | $83.83 | 11,826,700 |
| 2026-05-12 | $84.35 | 16,392,500 |
| 2026-05-11 | $82.56 | 16,460,500 |
| 2026-05-08 | $84.32 | 10,913,500 |
| 2026-05-07 | $87.01 | 13,272,900 |
| 2026-05-06 | $86.30 | 12,456,300 |
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, MÊnière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
đ° Latest News
A new blood test can help detect colon cancer, but itâs not as good as the test you hate to take
MarketWatch âĸ 2026-06-05T11:51:00Z
Is Omnipod 5âs Algorithm and Libre 3 Plus Upgrade Altering The Investment Case For Insulet (PODD)?
Simply Wall St. âĸ 2026-06-05T08:15:02Z
Abbott Addresses a Major Diabetes Care Gap With Tech Innovation
Zacks âĸ 2026-06-04T13:57:00Z
Jim Cramer Says âNo One Disputes the Science and Commercial Smarts of Abbottâ
Insider Monkey âĸ 2026-06-04T10:58:29Z
Assessing Abbott Laboratories (ABT) Valuation After New Diabetes Sensor And Cancer Screening Tailwinds
Simply Wall St. âĸ 2026-06-04T00:17:57Z
Medtronic Stock Is Defying a Market Selloff After Earnings. Hereâs Why.
Barrons.com âĸ 2026-06-03T20:45:00Z
QuidelOrtho's Respiratory Exposure Remains a Key Near-Term Risk
Zacks âĸ 2026-06-03T17:44:00Z
MiniMed expands Abbott partnership to add dual glucose-ketone sensor
MedTech Dive âĸ 2026-06-03T11:53:49Z
How A Steady Valuation Is Shaping The Evolving Abbott Laboratories (ABT) Investment Story
Simply Wall St. âĸ 2026-06-03T01:08:05Z
Why Investors Are Cautious on Abbott Laboratories (ABT)?
Insider Monkey âĸ 2026-06-02T16:33:36Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $17,885,000,000 | $17,366,000,000 | $16,698,000,000 | $17,888,000,000 |
| Cost Of Revenue | $19,319,000,000 | $18,706,000,000 | $17,975,000,000 | $19,142,000,000 |
| Total Revenue | $44,328,000,000 | $41,950,000,000 | $40,109,000,000 | $43,653,000,000 |
| Operating Revenue | $44,328,000,000 | $41,950,000,000 | $40,109,000,000 | $43,653,000,000 |
| Expenses | ||||
| Interest Expense | $493,000,000 | $559,000,000 | $637,000,000 | $558,000,000 |
| Total Expenses | $36,275,000,000 | $35,125,000,000 | $33,631,000,000 | $35,291,000,000 |
| Other Income Expense | $598,000,000 | $403,000,000 | $438,000,000 | $319,000,000 |
| Other Non Operating Income Expenses | $548,000,000 | $376,000,000 | $479,000,000 | $321,000,000 |
| Net Non Operating Interest Income Expense | $-185,000,000 | $-215,000,000 | $-252,000,000 | $-375,000,000 |
| Interest Expense Non Operating | $493,000,000 | $559,000,000 | $637,000,000 | $558,000,000 |
| Operating Expense | $16,956,000,000 | $16,419,000,000 | $15,656,000,000 | $16,149,000,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $6,524,000,000 | $13,402,000,000 | $5,723,000,000 | $6,933,000,000 |
| Net Interest Income | $-185,000,000 | $-215,000,000 | $-252,000,000 | $-375,000,000 |
| Interest Income | $308,000,000 | $344,000,000 | $385,000,000 | $183,000,000 |
| Normalized Income | $6,485,450,000 | $13,380,670,000 | $5,758,219,000 | $6,934,669,396 |
| Net Income From Continuing And Discontinued Operation | $6,524,000,000 | $13,402,000,000 | $5,723,000,000 | $6,933,000,000 |
| Total Operating Income As Reported | $8,053,000,000 | $6,825,000,000 | $6,478,000,000 | $8,362,000,000 |
| Net Income Common Stockholders | $6,524,000,000 | $13,402,000,000 | $5,723,000,000 | $6,933,000,000 |
| Net Income | $6,524,000,000 | $13,402,000,000 | $5,723,000,000 | $6,933,000,000 |
| Net Income Including Noncontrolling Interests | $6,524,000,000 | $13,402,000,000 | $5,723,000,000 | $6,933,000,000 |
| Net Income Continuous Operations | $6,524,000,000 | $13,402,000,000 | $5,723,000,000 | $6,933,000,000 |
| Pretax Income | $8,466,000,000 | $7,013,000,000 | $6,664,000,000 | $8,306,000,000 |
| Interest Income Non Operating | $308,000,000 | $344,000,000 | $385,000,000 | $183,000,000 |
| Operating Income | $8,053,000,000 | $6,825,000,000 | $6,478,000,000 | $8,362,000,000 |
| Depreciation Amortization Depletion Income Statement | $1,682,000,000 | $1,878,000,000 | $1,966,000,000 | $2,013,000,000 |
| Depreciation And Amortization In Income Statement | $1,682,000,000 | $1,878,000,000 | $1,966,000,000 | $2,013,000,000 |
| Amortization Of Intangibles Income Statement | $1,682,000,000 | $1,878,000,000 | $1,966,000,000 | $2,013,000,000 |
| Gross Profit | $25,009,000,000 | $23,244,000,000 | $22,134,000,000 | $24,511,000,000 |
| Net Income Discontinuous Operations | - | - | - | $0 |
| Special Income Charges | - | - | - | - |
| Per Share | ||||
| Diluted EPS | $3.72 | $7.64 | $3.26 | $3.91 |
| Basic EPS | $3.76 | $7.74 | $3.30 | $3.99 |
| Other | ||||
| Tax Effect Of Unusual Items | $11,450,000 | $5,670,000 | $-5,781,000 | $-330,604 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $12,025,000,000 | $10,763,000,000 | $10,585,000,000 | $12,133,000,000 |
| Total Unusual Items | $50,000,000 | $27,000,000 | $-41,000,000 | $-2,000,000 |
| Total Unusual Items Excluding Goodwill | $50,000,000 | $27,000,000 | $-41,000,000 | $-2,000,000 |
| Reconciled Depreciation | $3,116,000,000 | $3,218,000,000 | $3,243,000,000 | $3,267,000,000 |
| EBITDA (Bullshit earnings) | $12,075,000,000 | $10,790,000,000 | $10,544,000,000 | $12,131,000,000 |
| EBIT | $8,959,000,000 | $7,572,000,000 | $7,301,000,000 | $8,864,000,000 |
| Diluted Average Shares | $1,749,000,000 | $1,748,000,000 | $1,749,000,000 | $1,764,000,000 |
| Basic Average Shares | $1,736,599,451 | $1,731,697,991 | $1,734,076,358 | $1,737,795,021 |
| Diluted NI Availto Com Stockholders | $6,524,000,000 | $13,402,000,000 | $5,723,000,000 | $6,933,000,000 |
| Tax Provision | $1,942,000,000 | $-6,389,000,000 | $941,000,000 | $1,373,000,000 |
| Gain On Sale Of Security | $50,000,000 | $27,000,000 | $-41,000,000 | $-2,000,000 |
| Amortization | $1,682,000,000 | $1,878,000,000 | $1,966,000,000 | $2,013,000,000 |
| Research And Development | $2,942,000,000 | $2,844,000,000 | $2,741,000,000 | $2,888,000,000 |
| Selling General And Administration | $12,332,000,000 | $11,697,000,000 | $10,949,000,000 | $11,248,000,000 |
Fetched: 2026-05-24
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $22,569,000,000 | $17,909,000,000 | $6,109,000,000 | $3,433,000,000 |
| Total Assets | $86,713,000,000 | $81,414,000,000 | $73,214,000,000 | $74,438,000,000 |
| Total Non Current Assets | $60,717,000,000 | $57,758,000,000 | $50,544,000,000 | $49,214,000,000 |
| Other Non Current Assets | $18,422,000,000 | $16,459,000,000 | $7,097,000,000 | $6,033,000,000 |
| Investmentin Financial Assets | $597,000,000 | $553,000,000 | $555,000,000 | $558,000,000 |
| Goodwill And Other Intangible Assets | $29,561,000,000 | $29,755,000,000 | $32,494,000,000 | $33,253,000,000 |
| Other Intangible Assets | $5,526,000,000 | $6,647,000,000 | $8,815,000,000 | $10,454,000,000 |
| Current Assets | $25,996,000,000 | $23,656,000,000 | $22,670,000,000 | $25,224,000,000 |
| Inventory | $6,488,000,000 | $6,194,000,000 | $6,570,000,000 | $6,173,000,000 |
| Receivables | $10,569,000,000 | $9,495,000,000 | $8,821,000,000 | $8,881,000,000 |
| Other Receivables | $2,640,000,000 | $2,570,000,000 | $2,256,000,000 | $2,663,000,000 |
| Accounts Receivable | $7,929,000,000 | $6,925,000,000 | $6,565,000,000 | $6,218,000,000 |
| Allowance For Doubtful Accounts Receivable | $-490,000,000 | $-439,000,000 | $-444,000,000 | $-500,000,000 |
| Gross Accounts Receivable | $8,419,000,000 | $7,364,000,000 | $7,009,000,000 | $6,718,000,000 |
| Cash Cash Equivalents And Short Term Investments | $8,939,000,000 | $7,967,000,000 | $7,279,000,000 | $10,170,000,000 |
| Cash And Cash Equivalents | $8,522,000,000 | $7,616,000,000 | $6,896,000,000 | $9,882,000,000 |
| Non Current Deferred Assets | - | - | - | $6,033,000,000 |
| Non Current Deferred Taxes Assets | - | - | - | $6,033,000,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Net Debt | $4,407,000,000 | $6,509,000,000 | $7,783,000,000 | $6,891,000,000 |
| Total Debt | $13,860,000,000 | $15,021,000,000 | $15,628,000,000 | $17,716,000,000 |
| Long Term Debt And Capital Lease Obligation | $10,827,000,000 | $13,521,000,000 | $14,548,000,000 | $15,465,000,000 |
| Long Term Debt | $9,896,000,000 | $12,625,000,000 | $13,599,000,000 | $14,522,000,000 |
| Current Debt And Capital Lease Obligation | $3,033,000,000 | $1,500,000,000 | $1,080,000,000 | $2,251,000,000 |
| Current Debt | $3,033,000,000 | $1,500,000,000 | $1,080,000,000 | $2,251,000,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $33,942,000,000 | $33,513,000,000 | $34,387,000,000 | $37,533,000,000 |
| Total Non Current Liabilities Net Minority Interest | $17,446,000,000 | $19,356,000,000 | $20,546,000,000 | $22,044,000,000 |
| Other Non Current Liabilities | $2,538,000,000 | $2,586,000,000 | $2,386,000,000 | $3,804,000,000 |
| Tradeand Other Payables Non Current | $1,397,000,000 | $857,000,000 | $1,080,000,000 | - |
| Non Current Deferred Liabilities | $559,000,000 | $512,000,000 | $568,000,000 | $991,000,000 |
| Non Current Deferred Taxes Liabilities | $559,000,000 | $512,000,000 | $568,000,000 | $991,000,000 |
| Current Liabilities | $16,496,000,000 | $14,157,000,000 | $13,841,000,000 | $15,489,000,000 |
| Payables And Accrued Expenses | $13,463,000,000 | $12,657,000,000 | $12,761,000,000 | $13,238,000,000 |
| Payables | $6,588,000,000 | $6,434,000,000 | $6,392,000,000 | $6,475,000,000 |
| Other Payable | $682,000,000 | $621,000,000 | $650,000,000 | $638,000,000 |
| Dividends Payable | $1,097,000,000 | $1,024,000,000 | $955,000,000 | $887,000,000 |
| Total Tax Payable | $569,000,000 | $594,000,000 | $492,000,000 | $343,000,000 |
| Income Tax Payable | $569,000,000 | $594,000,000 | $492,000,000 | $343,000,000 |
| Accounts Payable | $4,240,000,000 | $4,195,000,000 | $4,295,000,000 | $4,607,000,000 |
| Equity | ||||
| Common Stock Equity | $52,130,000,000 | $47,664,000,000 | $38,603,000,000 | $36,686,000,000 |
| Total Equity Gross Minority Interest | $52,771,000,000 | $47,901,000,000 | $38,827,000,000 | $36,905,000,000 |
| Stockholders Equity | $52,130,000,000 | $47,664,000,000 | $38,603,000,000 | $36,686,000,000 |
| Gains Losses Not Affecting Retained Earnings | $-6,001,000,000 | $-7,906,000,000 | $-7,839,000,000 | $-8,051,000,000 |
| Other Equity Adjustments | $-6,001,000,000 | $-7,906,000,000 | $-7,839,000,000 | $-8,051,000,000 |
| Retained Earnings | $49,781,000,000 | $47,261,000,000 | $37,554,000,000 | $35,257,000,000 |
| Other | ||||
| Treasury Shares Number | $260,196,074 | $259,774,639 | $253,807,494 | $248,724,257 |
| Ordinary Shares Number | $1,736,599,451 | $1,731,697,991 | $1,734,076,358 | $1,737,795,021 |
| Share Issued | $1,996,795,525 | $1,991,472,630 | $1,987,883,852 | $1,986,519,278 |
| Tangible Book Value | $22,569,000,000 | $17,909,000,000 | $6,109,000,000 | $3,433,000,000 |
| Invested Capital | $65,059,000,000 | $61,789,000,000 | $53,282,000,000 | $53,459,000,000 |
| Working Capital | $9,500,000,000 | $9,499,000,000 | $8,829,000,000 | $9,735,000,000 |
| Capital Lease Obligations | $931,000,000 | $896,000,000 | $949,000,000 | $943,000,000 |
| Total Capitalization | $62,026,000,000 | $60,289,000,000 | $52,202,000,000 | $51,208,000,000 |
| Minority Interest | $641,000,000 | $237,000,000 | $224,000,000 | $219,000,000 |
| Treasury Stock | $17,177,000,000 | $16,844,000,000 | $15,981,000,000 | $15,229,000,000 |
| Capital Stock | $25,527,000,000 | $25,153,000,000 | $24,869,000,000 | $24,709,000,000 |
| Common Stock | $25,527,000,000 | $25,153,000,000 | $24,869,000,000 | $24,709,000,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Employee Benefits | $2,125,000,000 | $1,880,000,000 | $1,964,000,000 | $1,784,000,000 |
| Non Current Pension And Other Postretirement Benefit Plans | $2,125,000,000 | $1,880,000,000 | $1,964,000,000 | $1,784,000,000 |
| Long Term Capital Lease Obligation | $931,000,000 | $896,000,000 | $949,000,000 | $943,000,000 |
| Current Accrued Expenses | $6,875,000,000 | $6,223,000,000 | $6,369,000,000 | $6,763,000,000 |
| Investments And Advances | $918,000,000 | $886,000,000 | $799,000,000 | $766,000,000 |
| Other Investments | $321,000,000 | $333,000,000 | $244,000,000 | $208,000,000 |
| Available For Sale Securities | $597,000,000 | $553,000,000 | $555,000,000 | $558,000,000 |
| Goodwill | $24,035,000,000 | $23,108,000,000 | $23,679,000,000 | $22,799,000,000 |
| Net PPE | $11,816,000,000 | $10,658,000,000 | $10,154,000,000 | $9,162,000,000 |
| Accumulated Depreciation | $-13,406,000,000 | $-12,082,000,000 | $-11,779,000,000 | $-11,050,000,000 |
| Gross PPE | $25,222,000,000 | $22,740,000,000 | $21,933,000,000 | $20,212,000,000 |
| Construction In Progress | $2,567,000,000 | $2,488,000,000 | $2,064,000,000 | $1,484,000,000 |
| Other Properties | $17,571,000,000 | $15,517,000,000 | $15,179,000,000 | $14,164,000,000 |
| Buildings And Improvements | $4,543,000,000 | $4,207,000,000 | $4,161,000,000 | $4,053,000,000 |
| Land And Improvements | $541,000,000 | $528,000,000 | $529,000,000 | $511,000,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $3,976,000,000 | $3,700,000,000 | $3,946,000,000 | $3,805,000,000 |
| Work In Process | $904,000,000 | $840,000,000 | $807,000,000 | $680,000,000 |
| Raw Materials | $1,608,000,000 | $1,654,000,000 | $1,817,000,000 | $1,688,000,000 |
| Other Short Term Investments | $417,000,000 | $351,000,000 | $383,000,000 | $288,000,000 |
| Machinery Furniture Equipment | - | - | - | - |
Fetched: 2026-05-24
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $7,395,000,000 | $6,351,000,000 | $5,059,000,000 | $7,804,000,000 |
| Operating Activities | ||||
| Operating Cash Flow | $9,566,000,000 | $8,558,000,000 | $7,261,000,000 | $9,581,000,000 |
| Cash Flow From Continuing Operating Activities | $9,566,000,000 | $8,558,000,000 | $7,261,000,000 | $9,581,000,000 |
| Operating Gains Losses | $65,000,000 | $482,000,000 | $126,000,000 | $215,000,000 |
| Investing Activities | ||||
| Capital Expenditure | $-2,171,000,000 | $-2,207,000,000 | $-2,202,000,000 | $-1,777,000,000 |
| Investing Cash Flow | $-2,422,000,000 | $-2,338,000,000 | $-3,133,000,000 | $-1,740,000,000 |
| Cash Flow From Continuing Investing Activities | $-2,422,000,000 | $-2,338,000,000 | $-3,133,000,000 | $-1,740,000,000 |
| Net Other Investing Changes | $18,000,000 | $9,000,000 | $22,000,000 | $22,000,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-893,000,000 | $-1,295,000,000 | $-1,227,000,000 | $-3,795,000,000 |
| Financing Cash Flow | $-6,309,000,000 | $-5,404,000,000 | $-7,091,000,000 | $-7,636,000,000 |
| Cash Flow From Continuing Financing Activities | $-6,309,000,000 | $-5,404,000,000 | $-7,091,000,000 | $-7,636,000,000 |
| Net Other Financing Charges | $-82,000,000 | - | - | - |
| Cash Dividends Paid | $-4,116,000,000 | $-3,836,000,000 | $-3,556,000,000 | $-3,309,000,000 |
| Common Stock Dividend Paid | $-4,116,000,000 | $-3,836,000,000 | $-3,556,000,000 | $-3,309,000,000 |
| Net Common Stock Issuance | $-893,000,000 | $-1,295,000,000 | $-1,227,000,000 | $-3,795,000,000 |
| Other | ||||
| Repayment Of Debt | $-1,504,000,000 | $-660,000,000 | $-2,498,000,000 | $-753,000,000 |
| Issuance Of Debt | $5,000,000 | $223,000,000 | $2,000,000 | $7,000,000 |
| Interest Paid Supplemental Data | $545,000,000 | $604,000,000 | $662,000,000 | $563,000,000 |
| Income Tax Paid Supplemental Data | $1,933,000,000 | $1,723,000,000 | $1,475,000,000 | $1,864,000,000 |
| End Cash Position | $8,522,000,000 | $7,616,000,000 | $6,896,000,000 | $9,882,000,000 |
| Beginning Cash Position | $7,616,000,000 | $6,896,000,000 | $9,882,000,000 | $9,799,000,000 |
| Effect Of Exchange Rate Changes | $71,000,000 | $-96,000,000 | $-23,000,000 | $-122,000,000 |
| Changes In Cash | $835,000,000 | $816,000,000 | $-2,963,000,000 | $205,000,000 |
| Proceeds From Stock Option Exercised | $396,000,000 | $264,000,000 | $167,000,000 | $167,000,000 |
| Common Stock Payments | $-893,000,000 | $-1,295,000,000 | $-1,227,000,000 | $-3,795,000,000 |
| Net Issuance Payments Of Debt | $-1,614,000,000 | $-537,000,000 | $-2,475,000,000 | $-699,000,000 |
| Net Short Term Debt Issuance | $-115,000,000 | $-100,000,000 | $21,000,000 | $47,000,000 |
| Net Long Term Debt Issuance | $-1,499,000,000 | $-437,000,000 | $-2,496,000,000 | $-746,000,000 |
| Long Term Debt Payments | $-1,504,000,000 | $-660,000,000 | $-2,498,000,000 | $-753,000,000 |
| Long Term Debt Issuance | $5,000,000 | $223,000,000 | $2,000,000 | $7,000,000 |
| Net Investment Purchase And Sale | $-164,000,000 | $-141,000,000 | $-116,000,000 | $-33,000,000 |
| Sale Of Investment | $3,000,000 | $28,000,000 | $43,000,000 | $152,000,000 |
| Purchase Of Investment | $-167,000,000 | $-169,000,000 | $-159,000,000 | $-185,000,000 |
| Net Business Purchase And Sale | $-105,000,000 | $1,000,000 | $-837,000,000 | $48,000,000 |
| Sale Of Business | $0 | $1,000,000 | $40,000,000 | $48,000,000 |
| Purchase Of Business | $-105,000,000 | $0 | $-877,000,000 | $0 |
| Net PPE Purchase And Sale | $-2,171,000,000 | $-2,207,000,000 | $-2,202,000,000 | $-1,777,000,000 |
| Purchase Of PPE | $-2,171,000,000 | $-2,207,000,000 | $-2,202,000,000 | $-1,777,000,000 |
| Change In Working Capital | $-803,000,000 | $-9,217,000,000 | $-2,475,000,000 | $-1,519,000,000 |
| Change In Payables And Accrued Expense | $949,000,000 | $-7,672,000,000 | $-1,345,000,000 | $37,000,000 |
| Change In Payable | $949,000,000 | $-7,672,000,000 | $-1,345,000,000 | $37,000,000 |
| Change In Account Payable | $954,000,000 | $356,000,000 | $-760,000,000 | $420,000,000 |
| Change In Tax Payable | $-5,000,000 | $-8,028,000,000 | $-585,000,000 | $-383,000,000 |
| Change In Income Tax Payable | $-5,000,000 | $-8,028,000,000 | $-585,000,000 | $-383,000,000 |
| Change In Prepaid Assets | $-1,295,000,000 | $-796,000,000 | $-542,000,000 | $-75,000,000 |
| Change In Inventory | $195,000,000 | $-58,000,000 | $-232,000,000 | $-1,413,000,000 |
| Change In Receivables | $-652,000,000 | $-691,000,000 | $-356,000,000 | $-68,000,000 |
| Changes In Account Receivables | $-652,000,000 | $-691,000,000 | $-356,000,000 | $-68,000,000 |
| Stock Based Compensation | $664,000,000 | $673,000,000 | $644,000,000 | $685,000,000 |
| Depreciation Amortization Depletion | $3,116,000,000 | $3,218,000,000 | $3,243,000,000 | $3,267,000,000 |
| Depreciation And Amortization | $3,116,000,000 | $3,218,000,000 | $3,243,000,000 | $3,267,000,000 |
| Amortization Cash Flow | $1,682,000,000 | $1,878,000,000 | $1,966,000,000 | $2,013,000,000 |
| Amortization Of Intangibles | $1,682,000,000 | $1,878,000,000 | $1,966,000,000 | $2,013,000,000 |
| Depreciation | $1,434,000,000 | $1,340,000,000 | $1,277,000,000 | $1,254,000,000 |
| Gain Loss On Investment Securities | $65,000,000 | $482,000,000 | $126,000,000 | $215,000,000 |
| Net Income From Continuing Operations | $6,524,000,000 | $13,402,000,000 | $5,723,000,000 | $6,933,000,000 |
| Change In Other Working Capital | - | - | $-585,000,000 | $-383,000,000 |
Fetched: 2026-05-24